Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Alternating Antibiotics Eliminate Drug-Resistant Bacteria

By HospiMedica International staff writers
Posted on 20 Apr 2015
A new technique has been pioneered to help combat the rise of antibiotic-resistant bacteria that cause debilitating and often life-threatening human illness.

The technique uses sequential treatments, alternating doses of antibiotics which might offer effective treatment against bacterial infection. More...
This technique demonstrates that by administering sequential treatment also reduces the risk of the bacteria becoming resistant to antibiotics, and so maintaining the long-term effectiveness of the drugs.

Scientists at the University of Exeter (UK) working with colleagues in Mexico and Germany showed that sequential treatments can clear the bacterium when the equivalent combination treatment fails to, provided, that is, that the drugs are deployed in a suitably optimized, sequential manner. To demonstrate this, they used the following laboratory system: Escherichia coli K12 (AG100) was targeted with two antibiotics, erythromycin (a macrolide, ERY) and doxycycline (a tetracycline, DOX), that bind to different ribosomal RNA subunits, thereby inhibiting translation. While this is a nonclinical drug pairing, the commercial drug Synercid (comprising quinupristin and dalfopristin) also targets ribosomal RNA combinatorially.

After increasing dosages to their 70% inhibitory concentration (IC70) values, the following evidence of bacterial clearance by 96 hours was observed. Sixteen sequential treatments that produced some of the lowest population densities after 96 hours of treatment were examined, and, using spot tests, no live cells could be isolated for five of these treatments in all three replicates. In order to determine genetic changes due to the differential stresses found in drug-free conditions and in the sequential and combination treatments, two treatments at half maximal inhibitory concentration (IC50) that produced comparable densities at 96 hour were subjected to a whole-genome sequencing analysis and compared to the drug-free populations. All replicate populations from 24 hours and 96 hours were sequenced using the paired end technology on the ABI 7500 real time polymerase chain reaction system machine (Applied Biosystems; Grand Island, NY, USA).

Robert Beardmore, PhD, a professor and lead author of the study, said, “Our study finds a complex relationship between dose, bacterial population densities and drug resistance. As we demonstrate, it is possible to reduce bacterial load to zero at dosages that are usually said to be sub lethal and, therefore, are assumed to select for increased drug resistance.” The study was published on April 8, 2015, in the journal Public Library of Science Biology.

Related Links:

University of Exeter 
Applied Biosystems 



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.